BioSpace News Archive

Takeda Pharmaceutical Company Limited announced that its Board of Directors approved an executive compensation recoupment policy.

Phio Pharmaceuticals Corp. announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 1,713,064 shares of Phio’s common stock, at a purchase price of $2.335 per share, for gross proceeds of approximately $4.0 million in a registered direct offering priced at-the-market under Nasdaq rules.

PocketECG, MediLynx’s FDA approved remote monitoring systems: PocketECG Unified Arrhythmia Diagnostic System will be used for continuous streaming and analysis of full-disclosure ECG data, oxygen saturation, resting heart rate, patient symptoms and arrhythmia.

Sorrento Therapeutics, Inc., announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.

Advance Receipts Program to help dentists; grants available to non-profits for projects related to coronavirus relief

Hoffmann-La Roche Limited is pleased to announce the launch of the COVID-19 Open Innovation Challenge to encourage Canadians to help develop solutions to the challenges we face from the COVID-19 pandemic.

American Association of Nurse Anesthetists —The Centers for Medicare & Medicaid Services has temporarily suspended physician supervision requirements for Certified Registered Nurse Anesthetists —an action that the American Association of Nurse Anesthetists deems a critical step for CRNAs to serve the U.S. healthcare system more effectively during the COVID-19 pandemic.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced a grant of inducement awards to its Chief Legal and Business Officer, Jason A. Okazaki on March 26, 2020.

Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific AcroMetrix Coronavirus 2019 (COVID-19) RNA Control, its latest quality control product to monitor and validate COVID-19 molecular diagnostic tests.

REGENXBIO grants Ultragenyx exclusive, worldwide rights to NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder